Omeprazole (SKU A2845): Practical Research Workflow

Omeprazole is a small-molecule H+,K+-ATPase inhibitor used to establish controlled inhibition in gastric acid secretion research. The compound is chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide and is supplied as SKU A2845 at approximately 98% purity. Its dossier lists a molecular weight of 345.42 and molecular formula C17H19N3O3S.

The supplied product information gives activity benchmarks and handling specifications, but no directly matched paper evidence is available for this article. Accordingly, the guidance below separates product-dossier values from practical workflow recommendations and does not present independent efficacy results. The Omeprazole product page should be checked alongside the lot-specific documentation before an experiment is started.

What This Product Solves

Many acid secretion experiments require an inhibitor with a defined identity, stated purity, and a solvent system that can be controlled across treatment groups. A2845 addresses that need for studies involving proton pump inhibition, gastric acid secretion mechanisms, and antiulcer agent evaluation. It can be incorporated into enzyme-based inhibition assays or functional systems in which histamine-induced acid formation is measured.

The product dossier reports an IC50 of 5.8 µM for H+,K+-ATPase inhibition and an IC50 of 0.16 µM for histamine-induced acid formation. These values are useful as product-level reference points, not as universal expected results. Assay format, protein or cell preparation, incubation conditions, detection method, temperature, and vehicle exposure can all affect the apparent response.

For an antiulcer activity study, the compound can serve as a pharmacological comparison or pathway perturbation tool. In a peptic ulcer disease model, it may help define an acid-secretion-related experimental condition, but the supplied information does not validate any specific animal, tissue, or cellular model. The same boundary applies to broader research on gastric acid-related disorders: the reagent supports experimental investigation and does not establish clinical activity.

Researchers planning assay implementation can also consult Omeprazole (A2845): Technical Guidance for Acid Secretion Research, which is relevant to assay planning and research-use boundaries. For handling and quality-control considerations, Omeprazole A2845: Protocol and QC Guide provides a related workflow reference.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition assay; Value: IC50 5.8 µM; Applicability: biochemical proton pump inhibition experiments; Rationale: use as a dossier benchmark when designing a concentration-response study and comparing results generated under the same assay conditions; Evidence status: product dossier.
• Assay: Histamine-induced acid formation; Value: IC50 0.16 µM; Applicability: functional gastric acid secretion assays; Rationale: provides a product-level reference for an acid-formation endpoint, while emphasizing that the value should not be transferred between non-equivalent systems; Evidence status: product dossier.
• Assay: Stock preparation; Value: DMSO solubility of at least 17.27 mg/mL; Applicability: preparation of research stocks; Rationale: use DMSO as the primary stock solvent and check the resulting solution for precipitation before dilution into the assay vehicle; Evidence status: product dossier.
• Assay: Solid storage; Value: -20°C; Applicability: long-term storage of the neat compound; Rationale: retain the material as a solid and avoid relying on long-term storage of solution stocks; Evidence status: product dossier.

Workflow Setup and QC Checklist

1. Confirm identity and handling status

• Record the product name, SKU A2845, lot number, receipt date, and stated purity before opening the container.
• Confirm that the material was shipped under the specified blue-ice condition for small molecules and document any unusual package temperature or container damage.
• Keep the solid at -20°C. Remove only the amount required for preparation, limit unnecessary warming, and return the remaining solid to controlled storage.

2. Prepare the stock deliberately

Omeprazole is insoluble in water and ethanol according to the dossier, whereas DMSO supports solubility of at least 17.27 mg/mL. Weigh the compound using the stated molecular weight of 345.42, calculate the intended stock concentration, and dissolve it in DMSO with controlled mixing. Do not assume that an apparently clear mixture remains soluble after dilution into an aqueous assay buffer.

Inspect the stock and working dilution for cloudiness, visible particles, or precipitation. If precipitation occurs, do not treat the nominal concentration as the delivered concentration; re-evaluate the solvent composition and preparation sequence. Use freshly prepared working solutions when practical because long-term storage of solution form is not recommended.

3. Control assay comparability

• Include an untreated or vehicle control and keep DMSO exposure matched across all relevant conditions.
• For enzyme assays, define the protein preparation, substrate system, incubation sequence, and readout before applying the 5.8 µM dossier benchmark.
• For functional acid secretion experiments, distinguish basal acid formation from histamine-induced acid formation and apply the 0.16 µM value only as a product reference for the corresponding endpoint.
• Use a concentration-response design rather than relying on a single concentration when estimating assay-specific potency.

4. Document QC observations

Record the mass used, solvent lot, preparation time, stock appearance, dilution sequence, final vehicle content, storage exposure, and any precipitation observed. Retain the product documentation with the raw data. A result that differs from the dossier benchmark should first prompt review of identity, dilution accuracy, vehicle effects, endpoint definition, and compound handling before biological explanations are considered.

Common Failure Modes and Fixes

Precipitation after aqueous dilution

Likely cause: the DMSO stock was diluted too rapidly, the solvent fraction was not controlled, or the intended concentration exceeded practical solubility during the working step. Fix: confirm complete dissolution in DMSO, dilute gradually with mixing, inspect the final preparation, and use a lower working concentration or revised vehicle strategy when required.

Vehicle-dependent changes in the endpoint

Likely cause: treatment wells received different DMSO exposure or the vehicle affected the biochemical or functional readout. Fix: match vehicle across controls and treatments, include vehicle-only wells, and verify that the detection system remains suitable under the selected solvent condition.

Potency values are treated as interchangeable

Likely cause: the H+,K+-ATPase and histamine-induced acid formation IC50 values are being used as if they came from the same endpoint or protocol. Fix: keep the two benchmarks tied to their stated assay contexts and report the actual experimental conditions with the calculated response.

Loss of consistency between runs

Likely cause: repeated warming of the solid, prolonged solution storage, unrecorded stock age, or inconsistent dilution order. Fix: maintain a preparation log, store the solid at -20°C, avoid long-term solution storage, and use the same preparation sequence for comparative experiments.

Overinterpretation of a negative result

Likely cause: a lack of response is attributed to biological absence without checking compound delivery or assay suitability. Fix: confirm solubility, vehicle tolerance, endpoint responsiveness, and control performance before concluding that the target pathway is unaffected.

Scope and Limitations

A2845 is intended strictly for scientific research. It is not a diagnostic reagent and should not be used for medical treatment, clinical decision-making, or therapeutic claims. The product dossier supports use in gastric acid secretion research, proton pump inhibition studies, antiulcer activity study design, and related preclinical workflows, but it does not supply clinical outcomes or independent validation of a particular peptic ulcer disease model.

The reported IC50 values, solubility, purity, molecular identity, and storage conditions are product-level information. They should be cited as such in internal protocols and interpreted with the lot documentation. No directly matched paper evidence is asserted here, and no conclusion should be extended to gastric acid-related disorders in patients or to an in vivo outcome without separate model-specific evidence.

Conclusion

Omeprazole A2845 is most useful when its defined H+,K+-ATPase inhibition profile is paired with disciplined stock preparation, matched vehicle controls, and endpoint-specific interpretation. Use DMSO for preparation, retain the solid at -20°C, avoid long-term solution storage, and treat the 5.8 µM and 0.16 µM IC50 values as assay-context benchmarks rather than guaranteed results. These practices help distinguish compound-handling problems from genuine biological findings while keeping the work within a research-only scope.